Clinical Outcomes in Patients with Waldenström Macroglobulinemia (WM) Receiving Ibrutinib on the Phase 3 ASPEN Study ≥1 Year After Transitioning to ZanubrutinibRamon Garcia-Sanz,Roger Owen,Wojciech Jurczak,Meletios A. Dimopoulos,Helen McCarthy,Gavin Cull,Stephen Opat,Jorge J. Castillo,Marie José Kersten,Björn E. Wahlin,Sebastian Grosicki,Radha Prathikanti,Tian Tian,Heather Allewelt,Aileen Cleary Cohen,Constantine S. TamBlood（2023）引用 0|浏览9暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
